Valuation: Vitrolife AB

Market Cap 12.57B 1.27B 1.11B 1.05B 956M 1.79B 122B 1.79B 4.85B 62.24B 4.79B 4.68B 201B P/E 2026 *
25.5x
P/E 2027 * 20.6x
Enterprise Value 13.12B 1.33B 1.16B 1.09B 997M 1.87B 127B 1.87B 5.06B 64.96B 5B 4.89B 209B EV / Sales 2026 *
3.79x
EV / Sales 2027 * 3.38x
Free-Float
54.39%
Yield 2026 *
1.19%
Yield 2027 * 1.36%
Manager TitleAgeSince
Chief Executive Officer 52 01/08/2023
Director of Finance/CFO 55 10/10/2025
Chief Investment Officer 40 -
Director TitleAgeSince
Director/Board Member 63 19/04/2013
Chairman 70 01/08/2023
Chairman 55 -
Change 5-day change 1-year change 3-year change Capi.($)
-0.18%-6.68% - - 1.27B
-0.43%+1.00%+195.80%+572.70% 23.77B
-3.22%+9.67%+538.15%+93.41% 10.51B
+1.71%+2.83%-34.76%-17.79% 9.86B
-0.27%+12.73%-0.93% - 8.89B
-0.04%-0.54%+92.09%+54.75% 6.53B
+0.86%+1.06%-26.84%-20.16% 5.8B
+1.86%+3.08%-0.33%-9.77% 4.31B
+0.89%+8.41%+66.45%+71.51% 4.03B
+7.53%+10.21%-12.27%-25.05% 2.98B
Average +0.92%+4.50%+90.82%+89.95% 8.52B
Weighted average by Cap. +0.19%+3.65%+138.68%+218.76%

Financials

2026 *2027 *
Net sales 3.46B 351M 307M 288M 263M 493M 33.53B 494M 1.33B 17.12B 1.32B 1.29B 55.2B 3.71B 376M 329M 309M 282M 529M 35.95B 529M 1.43B 18.36B 1.41B 1.38B 59.19B
Net income 493M 49.96M 43.66M 41.04M 37.45M 70.28M 4.78B 70.3M 190M 2.44B 188M 184M 7.86B 609M 61.75M 53.97M 50.72M 46.29M 86.87M 5.9B 86.89M 235M 3.01B 232M 227M 9.72B
Net Debt 549M 55.7M 48.67M 45.75M 41.75M 78.35M 5.32B 78.37M 212M 2.72B 209M 205M 8.77B -26.74M -2.71M -2.37M -2.23M -2.03M -3.82M -259M -3.82M -10.32M -132M -10.19M -9.96M -427M
Logo Vitrolife AB
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!